A new generation of proprietary aptamers for more effective diagnosis and treatment

Find out more


Aptitude is hiring! See current openings.

Aptitude demonstrated the in vivo efficacy of two aptamer therapeutic programs

Aptitude has received 5 million dollars in non-dilutive funding

Aptitude started collaboration with a global leader in clinical diagnostics

Aptitude unlocks the potential of aptamers to solve the fundamental problems of antibodies

Imagine a synthetic antibody that:

binds with high affinity and specificity to targets such as small organics, peptides, proteins, cells, and tissues

discriminates targets which differ in structure by only a single functional group

is utilized as high sensitivity targeting reagents for research, diagnostics, and therapeutics

Imagine a company who can turn that dream into reality.

Welcome to the reality of Aptitude.


our team

Find out who is behind the Aptitude technology